Anemia: Types, Pathophysiology, and the Significance of Iron Deficiency

Posted on

Anemia: Types, Pathophysiology, and the Significance of Iron Deficiency

Anemia, characterized by a reduction in hemoglobin concentration or red blood cell (RBC) count below normal ranges, represents one of the most common hematological disorders worldwide. This condition diminishes the blood’s oxygen-carrying capacity, resulting in tissue hypoxia that manifests as fatigue, weakness, and decreased exercise tolerance. Anemia affects approximately 1.62 billion people globally, with varying prevalence across different demographic groups and geographical regions.

Classification of Anemias

Anemias can be classified based on red cell morphology or etiology:

Morphological Classification

  1. Microcytic (MCV < 80 fL): Includes iron deficiency anemia, thalassemias, anemia of chronic disease, and sideroblastic anemia.
  2. Normocytic (MCV 80-100 fL): Encompasses acute blood loss, hemolytic anemias, aplastic anemia, and early iron, B12, or folate deficiency.
  3. Macrocytic (MCV > 100 fL): Comprises megaloblastic anemias (vitamin B12 and folate deficiencies), alcoholism, liver disease, and myelodysplastic syndromes.

Etiological Classification

  1. Decreased Production:
    • Nutritional deficiencies (iron, vitamin B12, folate)
    • Bone marrow failure (aplastic anemia, myelodysplastic syndrome)
    • Anemia of chronic disease/inflammation
    • Endocrine disorders (hypothyroidism, hypopituitarism)
  2. Increased Destruction (Hemolytic):
    • Intrinsic defects (hereditary spherocytosis, sickle cell disease, thalassemias)
    • Extrinsic factors (autoimmune hemolytic anemia, microangiopathic hemolytic anemia, infections)
  3. Blood Loss:
    • Acute hemorrhage
    • Chronic bleeding (gastrointestinal, genitourinary, menstrual)

Iron Deficiency Anemia: The Global Health Challenge

Iron deficiency anemia (IDA) stands as the most prevalent form of anemia, affecting over 2 billion people worldwide. It accounts for approximately 50% of all anemia cases and disproportionately affects women of reproductive age, children, and individuals in low- and middle-income countries.

Pathophysiology of Iron Deficiency Anemia

The development of IDA follows a progressive sequence:

  1. Iron Depletion: Characterized by reduced iron stores with normal hemoglobin and red cell indices. Serum ferritin levels decrease while transferrin saturation remains normal.
  2. Iron-Deficient Erythropoiesis: Iron stores are exhausted, leading to insufficient iron for hemoglobin synthesis. Transferrin saturation decreases, and soluble transferrin receptor levels increase, but hemoglobin may still remain within normal limits.
  3. Iron Deficiency Anemia: Hemoglobin concentration falls below the threshold defining anemia, accompanied by microcytic, hypochromic red cells.

Iron plays a crucial role beyond oxygen transport, serving as an essential cofactor in many cellular processes including DNA synthesis, electron transport, and neurotransmitter metabolism. Hence, iron deficiency produces a spectrum of clinical manifestations beyond anemia.

Etiology of Iron Deficiency Anemia

The causes of IDA vary across different demographic groups:

  1. Increased Iron Requirements:
    • Rapid growth during infancy and adolescence
    • Pregnancy and lactation
    • Erythropoietin therapy
  2. Decreased Iron Intake or Absorption:
    • Dietary insufficiency
    • Malabsorption (celiac disease, gastrectomy, Helicobacter pylori infection)
    • Proton pump inhibitor use
    • Genetic defects in iron transport (IRIDA – iron-refractory iron deficiency anemia)
  3. Increased Iron Loss:
    • Menstruation
    • Gastrointestinal bleeding (peptic ulcer, inflammatory bowel disease, malignancy)
    • Genitourinary bleeding
    • Regular blood donation
    • Parasite infestations (hookworm, schistosomiasis)

Clinical Manifestations

IDA produces a range of symptoms reflecting both tissue hypoxia and iron’s role in cellular metabolism:

  • Fatigue, weakness, and reduced exercise capacity
  • Pica (craving for non-nutritive substances) and pagophagia (ice craving)
  • Koilonychia (spoon-shaped nails)
  • Angular cheilitis and glossitis
  • Restless legs syndrome
  • Impaired cognitive function and reduced work productivity
  • Increased susceptibility to infections
  • Developmental delays in children

Diagnosis

The diagnostic approach to IDA includes:

  1. Complete Blood Count: Reveals microcytic (low MCV), hypochromic (low MCH) anemia with increased red cell distribution width (RDW).
  2. Iron Studies:
    • Decreased serum ferritin (<30 ?g/L)
    • Decreased transferrin saturation (<16%)
    • Increased total iron-binding capacity (TIBC)
    • Elevated soluble transferrin receptor
    • Absence of stainable iron in bone marrow
  3. Additional Tests: May include peripheral blood smear examination, reticulocyte count, and hemoglobin electrophoresis to distinguish from other microcytic anemias.

Treatment Approaches

Management of IDA focuses on correcting the underlying cause and replenishing iron stores:

  1. Oral Iron Therapy:
    • Ferrous sulfate, ferrous gluconate, or ferrous fumarate
    • Recent evidence supports alternate-day dosing to improve absorption and reduce gastrointestinal side effects
    • Administration with vitamin C enhances absorption
  2. Parenteral Iron:
    • Indicated for intolerance to oral preparations, malabsorption, ongoing blood loss, or need for rapid replenishment
    • Modern formulations (iron carboxymaltose, iron isomaltoside, ferumoxytol) allow for rapid administration of high doses with improved safety profiles
  3. Nutritional Counseling: Encouraging consumption of iron-rich foods (red meat, legumes, leafy greens) and avoiding inhibitors of iron absorption (tea, coffee, calcium) with meals.
  4. Blood Transfusion: Reserved for severe, symptomatic anemia or active bleeding.

Conclusion

Anemia represents a significant global health burden, with iron deficiency anemia constituting its most prevalent form. Recent advances in understanding iron metabolism have led to improved diagnostic techniques and treatment strategies. The comprehensive management of anemia, particularly IDA, requires addressing the underlying cause, appropriate iron supplementation, and prevention strategies targeting high-risk populations. Public health initiatives focusing on iron fortification, deworming programs, and nutritional education continue to play vital roles in reducing the global prevalence of this preventable condition.

References

  1. Kassebaum NJ, Jasrasaria R, Naghavi M, et al. (2022). “A systematic analysis of global anemia burden from 1990 to 2020.” Blood, 139(7):1024-1037.
  2. Lopez A, Cacoub P, Macdougall IC, Peyrin-Biroulet L. (2023). “Iron deficiency anaemia.” Lancet, 401(10387):1537-1551.
  3. Camaschella C, Nai A, Silvestri L. (2022). “The mutual control of iron and erythropoiesis.” International Journal of Molecular Sciences, 23(3):1367.
  4. Moretti D, Goede JS, Zeder C, et al. (2022). “Oral iron supplements increase hepcidin and decrease iron absorption from daily or twice-daily doses in iron-depleted young women.” Blood, 136(11):1398-1409.
  5. Auerbach M, Adamson JW. (2023). “How we diagnose and treat iron deficiency anemia.” American Journal of Hematology, 97(12)